Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use.


Journal

Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435

Informations de publication

Date de publication:
01 06 2021
Historique:
aheadofprint: 10 12 2020
received: 20 05 2020
entrez: 10 12 2020
pubmed: 11 12 2020
medline: 28 5 2021
Statut: epublish

Résumé

Not available.

Identifiants

pubmed: 33299234
doi: 10.3324/haematol.2020.260133
pmc: PMC8168487
doi:

Substances chimiques

NPM1 protein, human 0
Nuclear Proteins 0
Nucleophosmin 117896-08-9

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

1767-1769

Références

Blood. 2007 Feb 1;109(3):874-85
pubmed: 17008539
Biomol Detect Quantif. 2015 Mar 11;3:9-16
pubmed: 27077029
J Clin Oncol. 2009 Aug 1;27(22):3650-8
pubmed: 19506161
N Engl J Med. 2016 Feb 4;374(5):422-33
pubmed: 26789727
J Clin Oncol. 2017 Jan 10;35(2):185-193
pubmed: 28056203
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Hematology Am Soc Hematol Educ Program. 2012;2012:35-42
pubmed: 23233558
Blood. 2013 Mar 21;121(12):2213-23
pubmed: 23321257
Haematologica. 2016 Feb;101(2):e55-8
pubmed: 26471486
Int J Hematol. 2009 Jul;90(1):1-5
pubmed: 19484332
Blood. 2018 Mar 22;131(12):1275-1291
pubmed: 29330221
J Clin Oncol. 2017 Apr 10;35(11):1223-1230
pubmed: 28221862
Int J Mol Sci. 2019 May 07;20(9):
pubmed: 31067725
Leukemia. 2006 Jun;20(6):1103-8
pubmed: 16541144
N Engl J Med. 2005 Jan 20;352(3):254-66
pubmed: 15659725

Auteurs

Auriane Lesieur (A)

CHU Lille, Laboratory of Hematology, F-59000 Lille.

Xavier Thomas (X)

Hospices Civils de Lyon, Lyon-Sud University Hospital, Department of Hematology, Lyon.

Olivier Nibourel (O)

CHU Lille, Laboratory of Hematology, F-59000 Lille, FRANCE; Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 - UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille.

Nicolas Boissel (N)

AP-HP, Saint-Louis Hospital, Department of Hematology, Saint-Louis Research Institute, Université de Paris, Paris.

Laurène Fenwarth (L)

CHU Lille, Laboratory of Hematology, F-59000 Lille, FRANCE; Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 - UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille.

Stéphane De Botton (S)

Gustave Roussy Institute, Department of Hematology, Villejuif.

Elise Fournier (E)

CHU Lille, Laboratory of Hematology, F-59000 Lille, FRANCE; Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 - UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille.

Karine Celli-Lebras (K)

AP-HP, Saint-Louis Hospital, Department of Hematology, Saint-Louis Research Institute, Université de Paris, Paris.

Emmanuel Raffoux (E)

AP-HP, Saint-Louis Hospital, Department of Hematology, Saint-Louis Research Institute, Université de Paris, Paris.

Christian Recher (C)

Toulouse Cancer University Institute, Department of Hematology, Toulouse.

Juliette Lambert (J)

CH Versailles, Department of Hematology, Le Chesnay.

Céline Berthon (C)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 - UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, FRANCE; CHU Lille, Department of Clinic Hematology, F-59000 Lille.

Arnaud Pigneux (A)

Bordeaux Haut-Lévêque University Hospital, Department of Hematology, Pessac.

Raphael Itzykson (R)

AP-HP, Saint-Louis Hospital, Department of Hematology, Saint-Louis Research Institute, Université de Paris, Paris.

Pascal Turlure (P)

CHU Limoges, Univ. Limoges, Department of Hematology, Limoges.

Cécile Pautas (C)

AP-HP, Department of Hematology, Henri Mondor Hospital, Créteil.

Jacques Vargaftig (J)

Curie Hospital, René Huguenin Hospital, Saint-Cloud.

Claude Preudhomme (C)

CHU Lille, Laboratory of Hematology, F-59000 Lille, FRANCE; Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 - UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille.

Hervé Dombret (H)

AP-HP, Saint-Louis Hospital, Department of Hematology, Saint-Louis Research Institute, Université de Paris, Paris.

Nicolas Duployez (N)

CHU Lille, Laboratory of Hematology, F-59000 Lille, FRANCE; Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 - UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille. nicolas.duployez@chru-lille.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH